It is, to our knowledge, the first study to evaluate the potential predictive role of VKORC1, CYP4F2, and GGCX polymorphisms for 5-year mortality in AIS patients who were not treated with VK antagonists. This evidence concerns the gene VKORC1 and androgen insensitivity syndrome.